AATec Medical develops recombinant alpha‑1 antitrypsin (AAT) biotherapeutics that target neutrophilic inflammation in respiratory diseases. Its platform combines anti‑protease, immunomodulatory, and anti‑infective actions and is delivered via a handheld inhalation device for direct lung dosing. The lead candidate, ATL‑105, is being advanced for non‑cystic fibrosis bronchiectasis and other chronic and acute lung conditions.
Funding
$19.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many respiratory diseases require targeted drug delivery directly to the airways for effective treatment. Current methods may not optimally deliver medication to the respiratory tract, limiting the local therapeutic effect.
Solution
AATec Medical is developing a therapeutic platform based on recombinant alpha-1 antitrypsin (AAT) to treat various respiratory diseases. Their lead product candidate, ATL-105, is designed as an inhalation treatment for conditions such as non-CF bronchiectasis, COPD, asthma, and pulmonary infections. The company's protein formulation, combined with inhalation technology, allows for direct drug administration to the respiratory tract, maximizing the local therapeutic effect.
Target Audience
The primary target audience includes patients suffering from respiratory diseases such as non-CF bronchiectasis, COPD, and asthma, as well as healthcare providers specializing in respiratory care.
Features
- Recombinant alpha-1 antitrypsin (AAT) as the active pharmaceutical ingredient
- Inhalation-based drug delivery system for targeted administration to the airways
- ATL-105 formulation specifically designed for non-CF bronchiectasis, COPD, asthma, and pulmonary infections